To evaluate the economic value of denosumab compared with alendronate and zoledronate in the treatment of postmenopausal women with osteoporosis (OP) from the perspective of Chinese health system.
Markov model was established and the treatment period was set to 5 years. The clinical efficacy, health benefits and cost data were obtained from published literatures. Lifetime disease outcomes, effectiveness and costs were calculated under each intervention. With the incremental cost-effectiveness ratio (ICER) as the index, the economy of each intervention was evaluated under the threshold of 3 times GDP per capita. Situation analysis, single factor sensitivity analysis and probability sensitivity analysis were used to test the robustness of the results.
The total costs were 19 268, 18 324 and 22 386 yuan in the groups of denosumab, alendronate and zoledronate, respectively. Total quality-adjusted life year (QALY) were 7.58, 7.53 and 7.56. Compared with alendronate, denosumab increased QALY by 0.05, ICER was 18 279 yuan per QALY, which was much lower than 1 times GDP per capita and more economical. Compared with zoledronate, denosumab resulted in an additional 0.03 QALYs and a lower cost, showing absolute advantage. Sensitivity analysis proved the robustness of the results.
In the treatment of postmenopausal women with OP, denosumab is more economical than alendronate and has absolute advantages over zoledronate.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |